Key facts
- PolySeq’s last known valuation is $69.5M (May 2023).
- It has raised $36.2M; the latest was Early Stage VC ($21.8M) in Mar 2026.
- Notable investors include IDG Capital, Tsinghua Innovation Ventures, BOC Financial Assets Investment, Chang Development, KSCY Holding Group — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for PolySeq
- ·The full record, as it builds
Funding rounds
No funding rounds for PolySeq are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PolySeq
Developer of a nanopore sequencing platform for the purpose of the fourth-generation gene sequencer and supporting reagent consumables. The company's product development is based on the principle of biological nanopore gene sequencing, combined with semiconductor integrated chips, deep learning and genomics technologies, enabling clients to increase the application rate of gene sequencing technology.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Website
- polyseq.com/
- Ownership
- Privately Held (backing)
PolySeq doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PolySeq shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PolySeq in its N-PORT filings yet. We sweep new filings monthly.